

# OpenText AI for life sciences

Unlock innovation and efficiency throughout  
the drug development value chain



The pharmaceutical industry is undergoing a technological revolution, led by generative AI (GenAI). While its impact on drug discovery is well known, GenAI also enhances innovation, streamlines operations, and improves decision-making. It enables better monitoring of manufacturing processes, leading to improved quality control, reduced costs, and faster time-to-market<sup>1</sup>.

Despite digital investments, many life sciences companies still struggle with siloed data and manual processes. GenAI offers a transformative opportunity to shift from reactive to proactive operations, enabling real-time insights, predictive analytics, and intelligent automation.

## OpenText vision

OpenText envisions a future where life sciences organizations use GenAI to:

- Accelerate R&D by identifying patterns in large datasets.
- Improve agility through optimized workflows and faster decision-making.
- Enhance manufacturing transparency and compliance.

OpenText™ Aviator™ solutions deliver innovative capabilities to reimagine work across all functional areas, delivering the AI building blocks required by life sciences. For example, Content Aviator can analyze regulatory documents to identify gaps and recommend actions, while also supporting pharmacovigilance by monitoring adverse event signals. Business Network Aviator can optimize asset availability with real-time, sensor-based monitoring for pre-clinical and production manufacturing equipment. And monitor in-transit shipment of goods in real time to optimize delivery routes for pharmaceutical products.



## OpenText solutions

Solution area	Relevance to life sciences	Benefit
AI-powered regulatory intelligence	Automate regulatory review and submission processes	Reduce time-to-market and improve compliance
Pharmacovigilance automation	Monitor safety signals from diverse data sources	Enhance patient safety and reduce risk
Clinical trial optimization	Analyze trial data and predict outcomes	Accelerate research and improve trial success rates
Content intelligence	Extract insights from unstructured documents	Improve decision-making and operational efficiency
AI-driven quality management	Identify quality issues early	Reduce product recalls and ensure compliance

## Business outcome

By adopting OpenText solutions, life sciences organizations can leverage predictive AI-led analytics, AI-powered conversational search, and generative AI to:

- Accelerate regulatory approvals.
- Reduce operational costs.
- Improve patient safety.
- Enhance agility and innovation.

These outcomes help organizations stay competitive and deliver better healthcare outcomes.

## Next steps

We recommend getting started with a proof of concept (POC) to explore how OpenText AI can support your goals. This includes an introductory meeting with key stakeholders, a joint roadmap exchange to align on AI strategy and a Business Value Consulting workshop to assess impact and define next steps.

## Why OpenText?

OpenText's AI strategy—opentext.ai—integrates GenAI and LLMs into information management. This empowers life sciences organizations to solve complex problems, enhance engagement, and make data-driven decisions faster and more effectively.



## Contact us

**Scott Lundstrom**  
Sr. Industry Strategist  
[slundstrom@opentext.com](mailto:slundstrom@opentext.com)